We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Noveltea is a premium alcoholic tea brand launched in Fenwick in April 2017. The company's products are vegan, gluten-free and low in sugar, and manufactured in minimalistic & up-cyclable lifestyle packaging. Thanks to its low-Alcohol by volume (ABV) portfolio, the brand has sold 350,000 bottles since its launch in 2017. The company experienced more than £100,000 worth of sales in April 2020 despite COVID-19 due to smart e-commerce channel utilisation. In 2020, the size of the global alcoholic drinks market is $1.587 trillion and is forecasted to grow by 3.5% (CAGR) over the next three years. The brand aims to become a major contender in this segment and grow its business. The company use the investment to focus on its core markets in the UK, Germany, and China, and enter the USA by 2020.

Pitch Rated

56%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £558,845
Medics2You's is a hybrid telehealth platform that connects patients with healthcare experts around the globe with focus on Africa through a smart device from anywhere, six days a week. The company has a pilot project underway in Nigeria, a nation which spends $500m-1bn annually on outbound healthcare tourism. Medics2You aims to reach out to over 100m people unable to access quality healthcare. Medics2You's partnership with Lantum has given the company access to 18000+ doctors and 3000 clinicians. The funds will be used to create the web portal, expand the team, set up local centres, and enhance marketing activities.

Pitch Rated

76%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £156,370
Mogees is a London-based company with the objective to disrupt the relationship between people and physical objects. Their patent-pending technology allows anyone to transform ordinary physical objects into ‘smart’ ones through the power of machine learning and a vibration sensor.
days to go: Expired investment: £1,153,867
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go: Expired investment: £5,877,517
Cotswold Raw is a premium producer of raw food for pets. They provide a convenient, natural and healthy way of operating a biologically appropriate raw feeding regime for dogs. Cotswold Raw are now currently producing over 3 tons of sausages and traditional mince per week.
days to go: Expired investment: £174,710
Bioepic is an app which enables users to easily and non-invasively measure their health status in just 30 seconds using just a smartphone. The app calculates pulse wave velocity, body temperature, blood pressure, heart rate variability chaos, vascular stiffness and the effectiveness of inhalers. 
days to go: Expired investment: £12,500
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph